In recent decades, our improved understanding of cancer has illuminated that we cannot treat all cancers as one disease — scientists have classified hundreds of types and found a myriad of genetic drivers underlying them. This means, just as cancer isn’t one disease, there cannot be just one way to treat all cancers.

“We’ve witnessed dramatic progress in how we treat a wide range of cancers, and our work at Merck has been foundational in how we treat metastatic disease, or cancer that has spread.”

Dr. Jane Healy
Vice president and head of oncology early development, Merck Research Laboratories

“This is just the tip of the iceberg. These advancements are helping to fuel the next generation of discoveries and drive progress in the way we care for people with all stages of cancer. We must push research forward that supports early discoveries and novel innovations to advance the future of cancer research,” Healy said.

Driving research toward treating certain cancers earlier

With the ultimate goal of providing patients with the greatest chance for survival, Merck's researchers are building a broad clinical development program focused on treating certain cancers at earlier stages.

“Expanding our research efforts into earlier stages of disease remains a top priority,” said Healy. “We’re pursuing research where we have the greatest potential to make a significant impact in helping reduce the risk of recurrence and improving survival.”

A robust pipeline of diverse approaches to advanced and earlier stages of cancer

In addition to driving research in earlier stages of cancer, Healy and her colleagues are investigating multiple mechanisms and modalities that may have the potential to address cancer in innovative ways. Through Merck's research and external collaborations, the company has developed a robust pipeline that encompasses diverse approaches to treating advanced and earlier stages of cancer across more than 20 novel mechanisms, including:

• Boosting anti-tumor immune responses: Learnings from recent advancements in cancer care have informed a more focused approach to research. Now, Merck is investigating foundational cancer treatments combined with negative immune regulators that play different roles in adjusting the immune response.
  
  The company is also exploring individualized neoantigen therapies, a growing area of research focused on sharpening the immune response against a person’s own tumor by developing a therapy unique to their tumor’s mutation.
  
• Tissue-specific targeting of chemotherapy to increase cancer cell sensitivity to immune responses: While chemotherapy remains an important treatment option, Merck's scientists are exploring how antibody-drug conjugates (ADCs), with novel chemotherapy-like payloads, can be used as a more targeted approach to deliver chemotherapy.
  
  Similarly, the company is pursuing research that enhances the ability of T cells to recognize and attack tumors.
  
• Impacting pathways that can drive cancer growth: Merck has identified opportunities for the direct targeting of cancer cell vulnerabilities and transcription factors that were previously considered untreatable. By designing therapeutic candidates that inhibit or degrade proteins and genes implicated in cancer pathways, the company is evaluating new ways to help address rare and difficult-to-treat cancers that currently have limited treatment options.

“We’re committed to investing in novel research where scientific opportunity and medical need converge.”

Dr. David Weinstock
Vice president of discovery oncology, Merck Research Laboratories

“These key areas of research are the cornerstones of our broad and diverse pipeline, with more than 2,250 ongoing clinical trials, which include more than 1,600 trials evaluating combination regimens. We remain dedicated to discovering new ways to fight this disease and optimizing existing approaches — all while continuing to lead in supporting the next generation of cancer research,” said Weinstock.

Researchers at Merck are committed to rapidly advancing leading-edge oncology research with the ultimate goal of improving the lives of people touched by cancer. To learn more about Merck’s focus on cancer research and treatments, visit Merck.com.

View original content here.

Merck & Co., Inc.

Merck & Co., Inc.

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

More from Merck & Co., Inc.